Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Mydecine Innovations Group Inc. (MYCOF)

Other OTC - Other OTC Delayed Price. Currency in USD
0.0901+0.0037 (+4.26%)
At close: 01:43PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Performance Outlook
Previous Close0.0865
Open0.0944
BidN/A x N/A
AskN/A x N/A
Day's Range0.0901 - 0.0944
52 Week Range0.0800 - 0.6560
Volume546
Avg. Volume2,676
Market Cap4.353M
Beta (5Y Monthly)3.11
PE Ratio (TTM)N/A
EPS (TTM)-0.3100
Earnings DateNov 14, 2023 - Nov 18, 2023
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A

Subscribe to Yahoo Finance Plus to view Fair Value for MYCOF

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • MYDECINE INNOVATIONS GROUP INC
    SDGR: Lowering target price to $29.00SCHRODINGER INC has an Investment Rating of HOLD; a target price of $29.000000; an Industry Subrating of Medium; a Management Subrating of Medium; a Safety Subrating of Low; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of High.
    Rating
    Fair Value
    Economic Moat
    4 days agoArgus Research
View more
  • GlobeNewswire

    Mydecine Innovations Group Announces Expected U.K. Dual Listing Admission Date

    VANCOUVER, British Columbia, Sept. 27, 2023 (GLOBE NEWSWIRE) -- Mydecine Innovations Group Inc. (“Mydecine” or the “Company”) (NEO:MYCO) (OTC:MYCOF) (FSE:0NFA) a biotechnology company engineering the next wave of innovative medications and treatment protocols to directly address mental health with a particular emphasis on addiction and PTSD, is pleased to announce expected admission of its common shares to begin trading on the Access Segment of the AQSE Growth Market in the UK is expected to tak

  • GlobeNewswire

    Mydecine Innovations Announces Amended Press Release Relating to the Closing of Prospectus Supplement Financing

    VANCOUVER, British Columbia, Sept. 20, 2023 (GLOBE NEWSWIRE) -- Mydecine Innovations Group Inc. (“Mydecine” or the “Company”) (NEO:MYCO) (OTC:MYCOF) (FSE:0NFA), a biotechnology company engineering the next wave of innovative medications and treatment protocols to directly address mental health with a particular emphasis on addiction and PTSD, is pleased to announce that further to the Company’s news release dated September 15, 2023 and September 19, 2023, the Company has closed its previously an

  • GlobeNewswire

    Mydecine Innovations Announces Closing of Prospectus Supplement Financing

    VANCOUVER, British Columbia, Sept. 19, 2023 (GLOBE NEWSWIRE) -- Mydecine Innovations Group Inc. (“Mydecine” or the “Company”) (NEO:MYCO) (OTC:MYCOF) (FSE:0NFA) a biotechnology company engineering the next wave of innovative medications and treatment protocols to directly address mental health with a particular emphasis on addiction and PTSD, is pleased to announce that further to the Company’s news release dated September 15, 2023, the Company has closed its previously announced offering by way

Advertisement
Advertisement